Swing Thesis This swing-trade for Conatus Pharmaceuticals, (Nasdaq: CNAT) is based on Technical Analysis (which aligns with some key dates) and a fundamental component. With regards to technical … [Read more...] about Technically Swinging CNAT
Preface The following was the result of discussion and collaboration between MS Money Moves and SCYNEXIS (Nasdaq: SCYX) Chief Financial Officer Eric Francois. We are thankful for his time and … [Read more...] about Interview with SCYNEXIS Following Positive Interim-Results From Phase 3 Open-Label FURI Study
Alzheimer disease (AD) is the most common form of dementia. AD is characterized by amyloid plaques and neurofibrillary tangles in the brain, with associated loss of synapses and neurons, … [Read more...] about TAU Me One More Time
On the heels of Gilead's (NYSE: GILD) disappointing phase 3 data readout in compensated cirrhosis from NASH (F4); Intercept Pharmaceutical (NYSE: ICPT) announced today positive results from their … [Read more...] about Intercept Announces Positive Top-Line Data From Phase 3 Study In Liver Fibrosis
Today ADMA Biologics (Nasdaq: ADMA) announced that they entered into a senior secured loan term facility with Perceptive Advisors for up to $72.5 million under 2 funding tranches. Let's get clarify … [Read more...] about ADMA Enters Into $72.5 Million Loan Facility With Perceptive Advisors
Novo Nordisk (NYSE: NVO) is a global healthcare company engaged in diabetes care, obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other … [Read more...] about Is Novo Nordisk Ready For Increased Biosimilar Competition?